Avanos Medical, Inc. ( (AVNS) ) has released its Q4 earnings. Here is a breakdown of the information Avanos Medical, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Avanos Medical, Inc. is a medical device company based in Alpharetta, Georgia, focusing on innovative healthcare solutions, particularly in reducing opioid use and aiding patient recovery post-surgery. The company recently announced its fourth quarter and full-year 2024 financial results, highlighting a 5% organic growth in the fourth quarter and a strong free cash flow of $83 million for the year. Despite these positive metrics, Avanos reported a significant net loss due to a $436.7 million impairment charge related to goodwill and intangible assets. Key financial highlights include a 3.6% increase in fourth-quarter net sales to $179.6 million and a full-year net sales increase of 2.2% to $687.8 million. Adjusted EBITDA for the year reached $107.6 million, reflecting improved operational efficiency. Looking ahead, Avanos anticipates 2025 net sales between $665 million and $685 million, with adjusted earnings per share ranging from $1.05 to $1.25. The company acknowledges market challenges but remains committed to its long-term strategy and expects to enhance its margin expansion by 2026.